Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06954662 · ClinicalTrials.gov registry record · Early Phase 1
A Targeted Amino Acid Supplement for People With Parkinson's Disease
A Early Phase 1 study of Parkinson Disease, Idiopathic, sponsored by UConn Health.
- Active
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06954662: Active Early Phase 1 study of Parkinson Disease, Idiopathic, sponsored by UConn Health.
NCT06954662 is a Early Phase 1 study of Parkinson Disease, Idiopathic that is active but no longer recruiting, run by UConn Health. The registered enrollment target is 15 participants, below the 97-participant average among 3 other Parkinson Disease, Idiopathic trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06954662, a Early Phase 1 study of Parkinson Disease, Idiopathic, is active but no longer recruiting, sponsored by UConn Health.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. The main question it aims to answer is: • Does an amino acid supplement that is specifically made for people with Parkinson disease have short-term improvements in nutrition deficiencies, while minimally interfering with Parkinson disease medication? Researchers will compare the short-term effects of this specialized nutrition supplement to a supplement that is available for everyone to purchase in a store (whey protein supplement-a milk by-product) and to an inactive supplement. Researchers will then check for the indicators of nutrition levels and the presence of dopamine medication in the blood. Researchers will also assess mood and movement abilities in participants. Participants will be asked to: * attend 4 study visits over the course of 4 weeks (initial orientation visit plus 3 intervention visits). * drink one of the 3 supplements (supplements will be mixed into water to create a beverage) at each of the 3 intervention visits. * participate in blood drawings and mood and movement assessments at each of the intervention visits. * engage in a phone call after each intervention visit to determine any delayed responses.
Primary Outcome
Circulating levodopa will be measured from the 10 blood samples at each of the three study visits.
Conditions Studied
Interventions
- DRUG Amino acid supplement
- DIETARY_SUPPLEMENT Whey Protein Supplement
- DIETARY_SUPPLEMENT Isonitrogenous Placebo Supplement
Study Locations (1)
Connecticut
- UConn Health, Clinical Research Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2025-09 |
| Phase | Early Phase 1 |
What the registry record for NCT06954662 still lists
NCT06954662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 97-participant average among 3 other Parkinson Disease, Idiopathic trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Parkinson Disease, Idiopathic appearing as the primary indexed condition, and to 3 interventions - of which Amino acid supplement is the first listed.
NCT06954662 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06954662 about?
NCT06954662 is a clinical study titled "A Targeted Amino Acid Supplement for People With Parkinson's Disease". The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. The main question it aims to answer is: • Does an amino aci...
What is the current status of trial NCT06954662?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2025-05-22. Estimated completion is 2025-09.
What conditions does trial NCT06954662 study?
This clinical trial studies the following conditions: Parkinson Disease, Idiopathic.
What interventions are being tested in trial NCT06954662?
The interventions under investigation include: Amino acid supplement (DRUG), Whey Protein Supplement (DIETARY_SUPPLEMENT), Isonitrogenous Placebo Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06954662?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06954662 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease, Idiopathic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease
RECRUITING · NA
-
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
RECRUITING · Phase 2
-
Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI